86 related articles for article (PubMed ID: 20211680)
1. A C-terminal hydrophobic, solvent-protected core and a flexible N-terminus are potentially required for human papillomavirus 18 E7 protein functionality.
Liu S; Tian Y; Greenaway FT; Sun MZ
Biochimie; 2010 Jul; 92(7):901-8. PubMed ID: 20211680
[TBL] [Abstract][Full Text] [Related]
2. HPV-18 E7 conjugates to c-Myc and mediates its transcriptional activity.
Wang YW; Chang HS; Lin CH; Yu WC
Int J Biochem Cell Biol; 2007; 39(2):402-12. PubMed ID: 17070091
[TBL] [Abstract][Full Text] [Related]
3. Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7.
Ohlenschläger O; Seiboth T; Zengerling H; Briese L; Marchanka A; Ramachandran R; Baum M; Korbas M; Meyer-Klaucke W; Dürst M; Görlach M
Oncogene; 2006 Sep; 25(44):5953-9. PubMed ID: 16636661
[TBL] [Abstract][Full Text] [Related]
4. E6*, the 50 amino acid product of the most abundant spliced transcript of the e6 oncoprotein in high-risk human papillomavirus, is a promiscuous folder and binder.
Heer A; Alonso LG; de Prat-Gay G
Biochemistry; 2011 Mar; 50(8):1376-83. PubMed ID: 21226480
[TBL] [Abstract][Full Text] [Related]
5. Predicted alpha-helix/beta-sheet secondary structures for the zinc-binding motifs of human papillomavirus E7 and E6 proteins by consensus prediction averaging and spectroscopic studies of E7.
Ullman CG; Haris PI; Galloway DA; Emery VC; Perkins SJ
Biochem J; 1996 Oct; 319 ( Pt 1)(Pt 1):229-39. PubMed ID: 8870673
[TBL] [Abstract][Full Text] [Related]
6. The relative ability of human papillomavirus type 6 and human papillomavirus type 16 E7 proteins to transactivate E2F-responsive elements is promoter- and cell-dependent.
Armstrong DJ; Roman A
Virology; 1997 Dec; 239(1):238-46. PubMed ID: 9426463
[TBL] [Abstract][Full Text] [Related]
7. HPV oncoprotein E6 is a structure-dependent DNA-binding protein that recognizes four-way junctions.
Ristriani T; Masson M; Nominé Y; Laurent C; Lefevre JF; Weiss E; Travé G
J Mol Biol; 2000 Mar; 296(5):1189-203. PubMed ID: 10698626
[TBL] [Abstract][Full Text] [Related]
8. Purification and characterisation of the E7 oncoproteins of the high-risk human papillomavirus types 16 and 18.
Fiedler M; Campo-Fernández B; Laich A; Moser B; Stöckl P; Jansen-Dürr P; Zwerschke W
J Virol Methods; 2006 Jun; 134(1-2):30-5. PubMed ID: 16384614
[TBL] [Abstract][Full Text] [Related]
9. Formation of well-defined soluble aggregates upon fusion to MBP is a generic property of E6 proteins from various human papillomavirus species.
Zanier K; Nominé Y; Charbonnier S; Ruhlmann C; Schultz P; Schweizer J; Travé G
Protein Expr Purif; 2007 Jan; 51(1):59-70. PubMed ID: 17055740
[TBL] [Abstract][Full Text] [Related]
10. Interaction of the HPV E7 proteins with the pCAF acetyltransferase.
Avvakumov N; Torchia J; Mymryk JS
Oncogene; 2003 Jun; 22(25):3833-41. PubMed ID: 12813456
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus type 45 E7 is a transforming protein inducing retinoblastoma protein degradation and anchorage-independent cell cycle progression.
Morandell D; Rostek U; Bouvard V; Campo-Fernández B; Fiedler M; Jansen-Dürr P; Zwerschke W
Virology; 2008 Sep; 379(1):20-9. PubMed ID: 18649911
[TBL] [Abstract][Full Text] [Related]
12. A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein.
Brokaw JL; Yee CL; Münger K
Virology; 1994 Dec; 205(2):603-7. PubMed ID: 7975265
[TBL] [Abstract][Full Text] [Related]
13. Specific recognition of four-way DNA junctions by the C-terminal zinc-binding domain of HPV oncoprotein E6.
Ristriani T; Nominé Y; Masson M; Weiss E; Travé G
J Mol Biol; 2001 Jan; 305(4):729-39. PubMed ID: 11162088
[TBL] [Abstract][Full Text] [Related]
14. Protein intrinsic disorder and human papillomaviruses: increased amount of disorder in E6 and E7 oncoproteins from high risk HPVs.
Uversky VN; Roman A; Oldfield CJ; Dunker AK
J Proteome Res; 2006 Aug; 5(8):1829-42. PubMed ID: 16889404
[TBL] [Abstract][Full Text] [Related]
15. The serine protease inhibitors TLCK and TPCK react with the RB-binding core of HPV-18 E7 protein and abolish its RB-binding capability.
Stöppler H; Stöppler MC; Adduci A; Koval D; Schlegel R
Virology; 1996 Mar; 217(2):542-53. PubMed ID: 8610446
[TBL] [Abstract][Full Text] [Related]
16. Metal-dependent folding and stability of nuclear hormone receptor DNA-binding domains.
Low LY; Hernández H; Robinson CV; O'Brien R; Grossmann JG; Ladbury JE; Luisi B
J Mol Biol; 2002 May; 319(1):87-106. PubMed ID: 12051939
[TBL] [Abstract][Full Text] [Related]
17. Domain substructure of HPV E6 oncoprotein: biophysical characterization of the E6 C-terminal DNA-binding domain.
Nominé Y; Charbonnier S; Ristriani T; Stier G; Masson M; Cavusoglu N; Van Dorsselaer A; Weiss E; Kieffer B; Travé G
Biochemistry; 2003 May; 42(17):4909-17. PubMed ID: 12718532
[TBL] [Abstract][Full Text] [Related]
18. Genus specific features of bovine papillomavirus E6, E7, E5 and E8 proteins.
Tomita Y; Ogawa T; Jin Z; Shirasawa H
Virus Res; 2007 Mar; 124(1-2):231-6. PubMed ID: 17126443
[TBL] [Abstract][Full Text] [Related]
19. A strained DNA binding helix is conserved for site recognition, folding nucleation, and conformational modulation.
Wetzler DE; Gallo M; Melis R; Eliseo T; Nadra AD; Ferreiro DU; Paci M; Sánchez IE; Cicero DO; de Prat Gay G
Biopolymers; 2009 Jun; 91(6):432-43. PubMed ID: 19156829
[TBL] [Abstract][Full Text] [Related]
20. The CXXC Zn binding motifs of the human papillomavirus type 16 E7 oncoprotein are not required for its in vitro transforming activity in rodent cells.
Braspenning J; Marchini A; Albarani V; Levy L; Ciccolini F; Cremonesi C; Ralston R; Gissmann L; Tommasino M
Oncogene; 1998 Feb; 16(8):1085-9. PubMed ID: 9519882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
